Skip Navigation
Leading research to understand, treat, and prevent infectious, immunologic, and allergic diseases
Skip Content Marketing
  • Share this:
  • submit to facebook
  • Tweet it
  • submit to reddit
  • submit to StumbleUpon
  • submit to Google +

September 2012 DAIDS Council-Approved Concepts

Concepts represent early planning stages for program announcements, requests for applications, or solicitations for Council's input. If NIAID publishes an initiative from one of these concepts, we link to it below. To find initiatives, go to the Opportunities and Announcements portal.

NB: Council approval does not guarantee that a concept will become an initiative.

Table of Contents

Functional Glycomics in HIV Vaccine Design

For the published request for applications, see the May 9, 2013, Guide announcement, Functional Glycomics in HIV Vaccine Design (R01).

HIV Database and Analysis Unit

Request for Proposals

Contact: Nancy Hershey

Objective: The HIV Database and Analysis Unit will provide a centralized resource for compiling and analyzing genetic sequences, immunological epitopes, and associated data for HIV-1 and related retroviruses. It will make this information widely available and easily accessible to the scientific community to assist with vaccine design and development, basic virology studies, HIV epidemiology, and appropriate treatment regimen development. This initiative fits under DAIDS Priority 1: Establish and integrate effective prevention strategies to halt the spread of HIV infection: Expand the knowledge of the basic biology of the structure, function, and mechanism of HIV gene products and their roles in HIV transmission, virulence, and pathogenesis, and use this information to design new or improved vaccines, microbicides, and replication inhibitors.

Description: This initiative will continue support for an HIV Database and Analysis Unit for compiling, analyzing, and disseminating HIV genetic sequence and associated data. Data collected include nucleotide sequences of HIV-1 and related lentiviruses together with associated biological and immunological data. Analysis of the data yields nucleotide alignments, amino acid sequences and alignments, classification of virus isolates both at the nucleotide and amino acid level, analysis of protein glycosylation patterns, and molecular epidemiological data about the spread of the viruses as well as their mutation rate and evolution. Immunological data, including cytotoxic T-cell epitopes, helper T-cell epitopes, and neutralizing epitopes, are also compiled and integrated with genetic sequence data. Information gathered through this database is made available through a Web site in the form of a compendium.

The Unit may also be expanded to serve as a repository and analytic facility for 454 "Deep Sequence" data for HIV sequences and as an anti-Env monoclonal antibody sequence database and tool to relate to potential germline gene sequences in both humans and nonhuman primates.

Staged Vaccine Development

For the published broad agency announcement, see the February 5, 2013, solicitation, Staged Vaccine Development.

Global HIV Vaccine Enterprise

Request for Proposals

Contact: Robert Corno

Objective: This initiative seeks to accelerate the discovery of an HIV/AIDS vaccine by providing support for the Global HIV/AIDS Vaccine Enterprise Secretariat. The contract supports the Enterprise Secretariat to organize meetings to facilitate consulting, collaborating, communicating, and data sharing among the Enterprise partners.

Description: The Global HIV Vaccine Enterprise is an alliance of independent organizations dedicated to accelerating the development of a preventative HIV vaccine. The Enterprise Secretariat works to ensure the Enterprise mission is supported by facilitating mutual coordination, collaboration, and knowledge sharing. The goal of this initiative is to continue to support the mission of the Enterprise, facilitated through the Enterprise Secretariat, whose core functions are to organize the annual AIDS Vaccine Conference, convene strategic think tanks, fora, and other meetings on identified priorities, and organize an annual funders forum to ensure alignment and coordination of resources.

No changes have been made in the scope or mechanism. The previous contract was awarded in FY 07 and will be funded through FY 13 using reprogrammed funds from DAIDS noncompeting base. The initiative request is to fund a renewal of the contract.

Multicenter AIDS Cohort Study (MACS)

For the published requests for applications, see the March 8, 2013, Guide announcements, Limited Competition—Multicenter AIDS Cohort Study (MACS) Clinical Research Sites (U01) and Limited Competition—Multicenter AIDS Cohort Study: Center for the Coordination, Analysis, and Management of the MACS (CAMACS) (UM1).

In Vitro Testing Resource for HIV Therapeutics and Topical Microbicides

For the published request for proposals, see the September 20, 2013, solicitation, In Vitro Testing Resource for HIV Therapeutics and Topical Microbicides.

Humanized Mouse Models for HIV Therapeutics Development

For the published request for proposals, see the December 31, 2012, solicitation, Humanized Mouse Models for HIV Drug Development.

Last Updated September 25, 2013

Last Reviewed October 10, 2012